Bacterial contamination prompts Zicam nasal decongestant recall

Share this article:
Bacterial contamination prompts Zicam nasal decongestant recall
Bacterial contamination prompts Zicam nasal decongestant recall

Matrixx Initiatives is voluntarily recalling one lot of Zicam Extreme Congestion Relief nasal gel due to contamination with Burkholderia cepacia, the FDA announced in a press release.

Although the bacteria pose little medical risk to healthy individuals, B. cepacia in a nasal spray has the potential to cause upper airway colonization and secondarily lead to respiratory infections in individuals with a compromised immune system or those with chronic lung conditions, such as cystic fibrosis.

The organism is resistant to many antibiotics and may be difficult to eradicate in this sensitive population if an infection occurs, according to the agency.

The affected lot is 2J23, is labeled with the expiration date 09/15 and bears the NDC number 62750-005-10. Zicam Extreme Congestion Relief is a nondrip liquid nasal gel and is packaged in a 0.5 oz. spray bottle. The product has been distributed to retailers nationwide throughout the United States.

So far, there have been no reports of related illness. ests on additional samples from the same lot have shown no evidence of B. cepacia contamination.

The FDA is urging healthcare providers to report any adverse reactions believed to be related to the nasal decongestant to the MedWatch Adverse Event Reporting program.

Share this article:
You must be a registered member of Clinical Advisor to post a comment.
close

Next Article in Web Exclusives

More in Web Exclusives

DHEA serum levels predict coronary heart disease risk

DHEA serum levels predict coronary heart disease risk

For elderly men, low serum levels of the adrenal sex hormone DHEA and its sulfate, DHEA-S, predict coronary heart disease risk.

Prenatal exposure to sodium valproate linked to lower IQ in offspring

Prenatal exposure to sodium valproate linked to lower ...

The IQ of children exposed to VPA was lower compared with children born to women without epilepsy and that of those exposed to carbamazepine.

FDA approves first Meningococcal B vaccine

FDA approves first Meningococcal B vaccine

The FDA has approved Trumenba, the first vaccine approved in the U.S. to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B